Jacqueline Boultwood

Jacqueline Boultwood

Auto-generated profile, based on publicly available information

Jacqueline Boultwood

Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2013 in Blood
Verified
Journal Article
Open access
PDF file
EPElli Papaemmanuil
Elli Papaemmanuil
MGMoritz Gerstung
Moritz Gerstung
LMLuca Malcovati
Luca Malcovati
STSudhir Tauro
Sudhir Tauro
GGGunes Gundem
Gunes Gundem
PCPeter J. Campbell
Peter J. Campbell
Key Points: MDS is characterized by mutations in >40 genes, a complex structure of gene-gene interactions and extensive subclonal diversification. The total number of oncogenic mutations and early detection of subclonal mutations are significant prognostic variables in MDS.

15 April 2008 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CLCharles Lawrie
Charles Lawrie
SGShira Gal
Shira Gal
HDHeather M. Dunlop
Heather M. Dunlop
BPBeena Pushkaran
Beena Pushkaran
ALAmanda P. Liggins
Amanda P. Liggins
DFDavid Favara
David Favara
Summary: Circulating nucleic acids have been shown to have potential as non‐invasive diagnostic markers in cancer. We therefore investigated whether microRNAs also have diagnostic utility by comparing levels of tumour‐associated MIRN155 (miR‐155), MIRN210 (miR‐210) and MIRN21 (miR‐21) in serum from diffuse large B‐cell lymphoma (DLBCL) patients (n = 60) with healthy controls (n = 43). Levels were higher in patient than control sera (P = 0·009, 0·02 and 0·04 respectively). Moreover, high MIRN21 expression was associated with relapse‐free survival (P = 0·05). This is the first description of circulating microRNAs and suggests that microRNAs have potential as non‐invasive diagnostic markers for DLBCL and possibly other cancers.

13 October 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
EPE. Papaemmanuil
E. Papaemmanuil
MCM. Cazzola
M. Cazzola
JBJ. Boultwood
J. Boultwood
LML. Malcovati
L. Malcovati
PVP. Vyas
P. Vyas
PCP.J. Campbell
P.J. Campbell
Myelodysplastic syndromes are a diverse and common group of chronic hematologic cancers. The identification of new genetic lesions could facilitate new diagnostic and therapeutic strategies. We used massively parallel sequencing technology to identify somatically acquired point mutations across all protein-coding exons in the genome in 9 patients with low-grade myelodysplasia. Targeted resequencing of the gene encoding RNA splicing factor 3B, subunit 1 (SF3B1), was also performed in a cohort of 2087 patients with myeloid or other cancers. We identified 64 point mutations in the 9 patients. Recurrent somatically acquired mutations were identified in SF3B1. Follow-up revealed SF3B1 mutations in 72 of 354 patients (20%) with myelodysplastic syndromes, with particularly high frequency among patients whose disease was characterized by ring sideroblasts (53 of 82 [65%]). The gene was also mutated in 1 to 5% of patients with a variety of other tumor types. The observed mutations were less deleterious than was expected on the basis of chance, suggesting that the mutated protein retains structural integrity with altered function. SF3B1 mutations were associated with down-regulation of key gene networks, including core mitochondrial pathways. Clinically, patients with SF3B1 mutations had fewer cytopenias and longer event-free survival than patients without SF3B1 mutations. Mutations in SF3B1 implicate abnormalities of messenger RNA splicing in the pathogenesis of myelodysplastic syndromes. (Funded by the Wellcome Trust and others.)

4 July 2010 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TEThomas Ernst
Thomas Ernst
ACAndrew J Chase
Andrew J Chase
JSJoannah Score
Joannah Score
CHClaire E Hidalgo-Curtis
Claire E Hidalgo-Curtis
CBCatherine Bryant
Catherine Bryant
NCNicholas C P Cross
Nicholas C P Cross

3 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
EBElsa Bernard
Elsa Bernard
YNYasuhito Nannya
Yasuhito Nannya
RHRobert P. Hasserjian
Robert P. Hasserjian
SDSean M. Devlin
Sean M. Devlin
HTHeinz Tuechler
Heinz Tuechler
EPElli Papaemmanuil
Elli Papaemmanuil

8 December 2011 in Blood
Verified
Journal Article
Open access
PDF file
LMLuca Malcovati
Luca Malcovati
EPElli Papaemmanuil
Elli Papaemmanuil
DBDavid T. Bowen
David T. Bowen
JBJacqueline Boultwood
Jacqueline Boultwood
MPMatteo G. Della Porta
Matteo G. Della Porta
OMon behalf of the Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative
on behalf of the Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative
In a previous study, we identified somatic mutations of SF3B1, a gene encoding a core component of RNA splicing machinery, in patients with myelodysplastic syndrome (MDS). Here, we define the clinical significance of these mutations in MDS and myelodysplastic/myeloproliferative neoplasms (MDS/MPN). The coding exons of SF3B1 were screened using massively parallel pyrosequencing in patients with MDS, MDS/MPN, or acute myeloid leukemia (AML) evolving from MDS. Somatic mutations of SF3B1 were found in 150 of 533 (28.1%) patients with MDS, 16 of 83 (19.3%) with MDS/MPN, and 2 of 38 (5.3%) with AML. There was a significant association of SF3B1 mutations with the presence of ring sideroblasts (P < .001) and of mutant allele burden with their proportion (P = .002). The mutant gene had a positive predictive value for ring sideroblasts of 97.7% (95% confidence interval, 93.5%-99.5%). In multivariate analysis including established risk factors, SF3B1 mutations were found to be independently associated with better overall survival (hazard ratio = 0.15, P = .025) and lower risk of evolution into AML (hazard ratio = 0.33, P = .049). The close association between SF3B1 mutations and disease phenotype with ring sideroblasts across MDS and MDS/MPN is consistent with a causal relationship. Furthermore, SF3B1 mutations are independent predictors of favorable clinical outcome, and their incorporation into stratification systems might improve risk assessment in MDS.